Radiolysis Control in 18F-FACBC PET Agents via pH and Sugar Alcohol Stabilization

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Radioactive fluorine-labeled amino acid compounds, such as [18F]-FACBC, face challenges with radiolysis during delivery, leading to decreased radiochemical purity, which is difficult to inhibit due to the short half-life of positron nuclides used in PET agents, making it hard to maintain impurity levels below 1.0% and assess their impact on tumor accumulation.

Innovation Solution

Maintaining the pH value of the solution between 2.0 and 5.9, preferably with hydrochloric acid, and adding sugar alcohols like erythritol, xylitol, or sorbitol to reduce radiolysis, while adjusting the radioactive concentration to ensure sufficient radioactivity for PET imaging.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If radioactive fluorine-labeled amino acid compounds are used for PET imaging, then high sensitivity and specificity for tumor detection are achieved, but radiolysis occurs during delivery causing decreased radiochemical purity

Engineering Contradiction:
Improvetumor detection accuracyVSAvoidradiochemical purity
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

A buffer substance is introduced as an intermediary to protect the radioactive fluorine-labeled amino acid compound from radiolysis during delivery. The buffer absorbs the harmful effects of radiation, preventing decomposition of the active compound while maintaining its tumor detection functionality.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The pH value of the solution is changed and controlled within a specific range (2.0-5.9) to reduce radiolysis. By adjusting this physical parameter, the stability of the radioactive compound is improved during delivery without affecting its diagnostic performance.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If the maximum daily dosage of effective component is as small as not more than 1 mg, then high specificity to diseases is achieved, but impurities exceeding 1.0% require structure determination according to ICH guidelines

Engineering Contradiction:
Improvediagnostic specificityVSAvoidimpurity control
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

The buffer substance, intended to protect against radiolysis, is converted into a beneficial element that also helps control impurity levels. By preventing radiolysis-induced decomposition, the buffer reduces the formation of degradation products, thereby maintaining impurity levels below the 1.0% threshold specified in ICH guidelines.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Stability of the object's composition

If radiolysis is inhibited by adding buffer or organic compounds, then radiochemical stability is improved, but the complexity of the composition increases

Engineering Contradiction:
Improveradiochemical stabilityVSAvoidcomposition complexity
Core Design Contradiction:
Stability of the object's compositionVSDevice complexity

Solution Approach 1:

Instead of adding complex protective substances, the invention simplifies the approach by changing the pH parameter of the existing solution to within the range of 2.0-5.9. This parameter adjustment provides radioprotection without significantly increasing composition complexity, as it utilizes the buffer capacity already present in the formulation.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP2106808B1Radioactive diagnostic imaging agent comprising 1-amino-3-[18f]fluorocyclobutanecarboxylic acid
Publication Date: 2018.02.21 NIHON MEDI PHYSICS CO LTD
  • EP2106808B1 patent drawingFigure 1~2
  • EP2106808B1 patent drawing
  • EP2106808B1 patent drawing

AI summary

A composition comprising a radioactive fluorine-labeled amino acid compound is provided, which can be prevented from radiolysis. Disclosed is a composition which comprises a solution containing a radioactive fluorine-labeled amino acid compound as an effective ingredient, in which the pH value of the solution is kept at 2.0-5.9, more preferably 2.0-4.9 in order to inhibit radiolysis. Also, it is possible to further inhibit radiolysis by adding thereto a pharmaceutical additive capable of inhibiting radiolysis, such as a sugar, a sugar alcohol and a sugar lactone, whilst the pH is kept at 2.0-5.9.